Literature DB >> 10928772

Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization.

C Cursiefen1, C Rummelt, M Küchle.   

Abstract

PURPOSE: To analyze presence and distribution of vascular endothelial growth factor (VEGF), transforming growth factor (TGF)alpha, and TGFbeta1 in human corneas with neovascularization due to different corneal diseases.
METHODS: Indirect immunohistochemistry for VEGF, TGFalpha, and TGFbeta1, was performed on paraffin-embedded corneas obtained by keratoplasty. Corneas from each of the four main groups of histopathologic diagnoses associated with corneal neovascularization were analyzed (scarring after keratitis, graft rejection/insufficiency, acute necrotizing keratitis, scarring after mechanical/chemical injury). Subclassification of inflammatory infiltrates was done using immunohistochemistry for CD3 (T-lymphocytes) and CD68 (macrophages).
RESULTS: The analyzed angiogenic factors were detectable in corneas from all four histopathologic groups in a similar distribution; capillary endothelial cells, stromal and intravascular inflammatory cells (T-lymphocytes, macrophages), and basal corneal epithelial cells stained positive for the tested angiogenic factors.
CONCLUSION: The angiogenic factors VEGF, TGFalpha, and TGFbeta1 are detectable in human corneas with neovascularization. Their distribution is quite uniform in different corneal diseases, resulting in corneal angiogenesis. An antiangiogenic therapy inhibiting corneal neovascularization by antagonizing angiogenic factors would have to counteract several angiogenic factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928772     DOI: 10.1097/00003226-200007000-00025

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  30 in total

1.  Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation.

Authors:  C Cursiefen; C Hofmann-Rummelt; M Küchle; U Schlötzer-Schrehardt
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

2.  Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).

Authors:  Roberta P A Manzano; Gholam A Peyman; Palwasha Khan; Petros E Carvounis; Muhamet Kivilcim; Min Ren; Jonathan C Lake; Patricia Chévez-Barrios
Journal:  Br J Ophthalmol       Date:  2006-12-19       Impact factor: 4.638

Review 3.  Clinical correlates of common corneal neovascular diseases: a literature review.

Authors:  Nizar Saleh Abdelfattah; Mohamed Amgad; Amira A Zayed; Hamdy Salem; Ahmed E Elkhanany; Heba Hussein; Nawal Abd El-Baky
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

4.  The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization.

Authors:  Banu Torun Acar; Elvin Halili; Suphi Acar
Journal:  Int Ophthalmol       Date:  2013-02-13       Impact factor: 2.031

Review 5.  [Inhibition of angiogenesis in the anterior chamber of the eye].

Authors:  F Bock; Y König; T Dietrich; P Zimmermann; M Baier; C Cursiefen
Journal:  Ophthalmologe       Date:  2007-04       Impact factor: 1.059

6.  Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.

Authors:  Young Sang Han; Ji Eun Lee; Ji Won Jung; Jong Soo Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-25       Impact factor: 3.117

7.  The effect of bevacizumab on corneal neovascularization in rabbits.

Authors:  Wung-Jae Kim; Hee-Ok Jeong; Sung-Kun Chung
Journal:  Korean J Ophthalmol       Date:  2010-08-03

8.  IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1.

Authors:  Vijay K Kommineni; Chandrasekharam N Nagineni; Abitha William; Barbara Detrick; John J Hooks
Journal:  Biochem Biophys Res Commun       Date:  2008-07-17       Impact factor: 3.575

9.  Corneal neovascularization during experimental fungal keratitis.

Authors:  Xiaoyong Yuan; Kirk R Wilhelmus
Journal:  Mol Vis       Date:  2009-09-29       Impact factor: 2.367

10.  Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a 'first in man' phase I investigation.

Authors:  Hermann Kain; David Goldblum; Bernard Geudelin; Eric Thorin; Christoph Beglinger
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.